SENS Stock Up as Eversense 365 Enters AID Market With twiist System

Core Insights - Senseonics Holdings, Inc. (SENS) has achieved a significant commercialization milestone with the launch of the Eversense 365 continuous glucose monitor (CGM) integrated with the twiist automated insulin delivery (AID) system, marking the first pairing of a one-year, implantable CGM with an AID platform [2][3][7] Company Developments - The integration with Sequel MedTech enhances diabetes management by reducing sensor changes and enabling automated insulin adjustments, with broader availability expected by March 2026 [3][10] - The Eversense 365's implantable design allows for uninterrupted glucose monitoring for up to one year, addressing common issues associated with frequent sensor changes [9] - SENS reported a strong improvement in its third-quarter 2025 financial performance, with total revenue rising to $8.1 million from $4.3 million year-over-year, driven by a 160% increase in new patient growth in the U.S. [12] - The company achieved a gross profit of $3.5 million in the quarter, a significant improvement from a gross loss of $4.1 million a year ago, indicating progress in cost structure and operating efficiency [14] Market Position and Trends - Following the announcement of the Eversense 365 launch, SENS shares gained 8%, although they have declined 28.8% over the past six months compared to a 10.5% decline in the industry [4] - The global blood glucose monitoring devices market is projected to grow from $15.53 billion in 2025 to $30.18 billion by 2033, expanding at a CAGR of 8.8% from 2026 to 2033, driven by the increasing prevalence of diabetes [11]